| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3414 | Mls-2064 | Potent inhibitor of STAT3 and Akt signaling |
|
| DCC3415 | Mls-2384 | Novel dual JAK/Src kinase inhibitor, suppressing growth of diverse cancer cells |
|
| DCC3416 | Mls8091 | Novel inhibitor of human cytomegalovirus (HCMV) infection |
|
| DCC3417 | Ml-sa3 | Potent agonist of TRPML channels specifically activating lysosomal ML1 currents |
|
| DCC3418 | Mlt-695 | Novel potent and selective MALT-1 protease inhibitor, showing improved solubility and permeability in comparison with MLT-748 |
|
| DCC3419 | Mmg-0358 | Novel potent IDO1 inhibitor, showing low cytotoxicity and higher selectivity for IDO1 over TDO enzyme |
|
| DCC3420 | Mmh371 | Novel potent and selective HDAC8 inhibitor |
|
| DCC3421 | Mmh409 | Novel potent and selective HDAC8 inhibitor |
|
| DCC3422 | Mmh410 | Novel potent and selective HDAC8 inhibitor |
|
| DCC3423 | Mmp13-in-t26c | Novel highly potent and selective MMP13 inhibitor |
|
| DCC3424 | M-mpep | Negative allosteric modulator (NAM) ligand for the mGlu5 receptor |
|
| DCC3425 | Mmpl3-in-e11 | Novel Mmpl3 inhibitor, indirectly blocking translocation of Trehalose Monomycolates across the IM |
|
| DCC3426 | Mms-350 | Highly water-soluble antifibrotic agent, reducing the profibrotic phenotype induced in vitro in primary human fibroblasts and ameliorating bleomycin-induced pulmonary fibrosis in vivo |
|
| DCC3427 | Mmv001239 | Novel inhibitor of lanosterol-14-alpha-demethylase (TcCyp51) |
|
| DCC3428 | Mmv006764 | The first small-molecule anti-plasmodial agent, disrupting rosetting, simultaneously restoring microcirculation and reduce parasite load |
|
| DCC3429 | Mmv007564 | Novel antimalarial agent against asexual stages of P. falciparum |
|
| DCC3430 | Mmv007839 | Novel potent Plasmodium lactate transporter PfFNT |
|
| DCC3431 | Mmv008138 | Novel MEP pathway-targeting antimalarial agent |
|
| DCC3432 | Mmv009108 | Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones |
|
| DCC3433 | Mmv019662 | Novel Inhibitor of Plasmodium falciparum |
|
| DCC3434 | Mmv022029 | Novel antischistosomal agent against chronic S. mansoni infection |
|
| DCC3435 | Mmv022478 | Novel antischistosomal agent against chronic S. mansoni infection |
|
| DCC3436 | Mmv028038 | Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones |
|
| DCC3437 | Mmv085203 | Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites |
|
| DCC3438 | Mmv396719 | Novel antimalarial agent against Plasmodium falciparum |
|
| DCC3439 | Mmv665916 | Novel antimalarial agent, targeting P. falciparum farnesyltransferase PfFT, showing remarkable growth inhibition with EC50 value of 0.4 µM and presenting good selectivity index (SI > 250) |
|
| DCC3440 | Mmv666693 | Selective allosteric inhibitor of Plasmodium Kinesin-5 |
|
| DCC3441 | Mmv675939 | Novel potent inhibitor of P. falciparum asexual blood stages, inhibiting heme detoxification |
|
| DCC3442 | Mmv676477 | Novel potent broad antiparasitic agent against intracellular Leishmania amastigotes, Trypanosoma brucei, and Plasmodium falciparum |
|
| DCC3443 | Mmv693183 | First-in-class acetyl-CoA synthetase (AcAS) inhibitor, showong single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocking P. falciparum transmission to Anopheles mosquitoes |
|
